Novabay Pharmaceuticals, INC. (NBY) — 10-Q Filings

10-Q Filings (6)

• NovaBay Pivots to Profit Amid Divestitures, Eyes Blockchain — Nov 7, 2025 Risk: high
  NovaBay Pharmaceuticals, Inc. reported a net income of $4.455 million for the nine months ended September 30, 2025, a significant improvement from a net loss of
• NovaBay Swings to Profit on Divestitures, Eyes Liquidation or New Strategy — Aug 14, 2025 Risk: high
  NovaBay Pharmaceuticals, Inc. (NBY) reported a net income of $5.748 million for the six months ended June 30, 2025, a significant turnaround from a net loss of
• NovaBay Pharmaceuticals Q1 2025 Revenue at $5.5M — May 15, 2025 Risk: medium
  NovaBay Pharmaceuticals, Inc. filed its Q1 2025 10-Q report on May 15, 2025, detailing financial performance for the quarter ending March 31, 2025. The company
• NovaBay Pharma Q3 2024: Focus on Financing and Divestitures — Nov 7, 2024 Risk: medium
  NovaBay Pharmaceuticals, Inc. filed its Q3 2024 10-Q report on November 7, 2024, for the period ending September 30, 2024. The company reported on its financial
• NovaBay Pharmaceuticals Q2 2024: Warrant Offerings Detailed — Aug 13, 2024 Risk: medium
  NovaBay Pharmaceuticals, Inc. reported its Q2 2024 results, ending June 30, 2024. The company's financial performance and operational updates were detailed in t
• NovaBay Pharmaceuticals, Inc. Files 10-Q for Q1 2024 — May 9, 2024 Risk: medium
  NovaBay Pharmaceuticals, Inc. (NBY) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. NovaBay Pharmaceuticals reported $0.01 EPS for Q1 2024. Total r

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX